On the stock market since 2022, it operates in the world of health and science. It has 2,029 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (-1% a year).
If every debt were paid off today, $0 would still be left in the vault — a solid cushion for hard times.
The stock trades 29% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Over the last 3 years, sales fell about 0% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, EMBCV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EMBCV is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.